Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
-
Published:2019-07
Issue:
Volume:116
Page:137-147
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Reck MartinORCID,
Schenker Michael,
Lee Ki Hyeong,
Provencio Mariano,
Nishio Makoto,
Lesniewski-Kmak Krzysztof,
Sangha Randeep,
Ahmed Samreen,
Raimbourg Judith,
Feeney Kynan,
Corre Romain,
Franke Fabio Andre,
Richardet Eduardo,
Penrod John R.,
Yuan Yong,
Nathan Faith E.,
Bhagavatheeswaran Prabhu,
DeRosa Michael,
Taylor Fiona,
Lawrance Rachael,
Brahmer Julie
Funder
Bristol-Myers Squibb
Ono Pharmaceutical
Subject
Cancer Research,Oncology
Cited by
167 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献